

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 29, 2002, 18:10:12 ; Search time 2037.65 Seconds
(without alignments)
297.828 Million cell updates/sec

Title: US-09-310-844C-23

Perfect score: 29

Sequence: 1 nnnnauuncuunungnaagcccnangn 29

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1797656 seqs, 10463268293 residues 843946

Minimum DB seq length: 0
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl:*
1: gb_ba:*
2: gb_htg:*
3: gb_in:*
4: gb_om:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sy:*
12: gb_un:*
13: gb_vl:*
14: gb_vl:*
15: em_ba:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_or:*
22: em_ov:*
23: em_pat:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sy:*
28: em_un:*
29: em_vl:*
30: em_htg_hum:*
31: em_htg_inv:*
32: em_htg_other:*
33: em_htgo_inv:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
------------	-------	-------------	--------	-------	-------------

C	1	14.4	49.7	100	5	AF174506	AF174506 Bufo gary
C	2	13.2	45.5	100	5	AF174511	AF174511 Bufo mela
C	3	13.2	45.5	100	5	AF174512	AF174512 Bufo mela
C	4	13.2	45.5	100	5	AF174513	AF174513 Bufo mela
C	5	13.2	45.5	100	5	AF174514	AF174514 Bufo mela
C	6	13.2	45.5	100	5	AF174515	AF174515 Bufo mela
C	7	13.2	45.5	100	5	AF174516	AF174516 Bufo mela
C	8	13.2	45.5	100	5	AF174517	AF174517 Bufo mela
C	9	13.2	45.5	100	5	AF174518	AF174518 Bufo mela
C	10	13.2	45.5	100	5	AF174519	AF174519 Bufo mela
C	11	13.2	45.5	100	5	AF174520	AF174520 Bufo mela
C	12	13.2	45.5	100	5	AF174521	AF174521 Bufo mela
C	13	13.2	45.5	100	5	AF174522	AF174522 Bufo mela
C	14	12.8	44.1	100	5	AF174501	AF174501 Bufo hima
C	15	12.8	44.1	100	5	AF174505	AF174505 Bufo gary
C	16	12.8	44.1	100	5	AF174507	AF174507 Bufo gary
C	17	12.8	44.1	100	5	AF174508	AF174508 Bufo bank
C	18	12.8	44.1	100	5	AF174509	AF174509 Bufo bank
C	19	12.2	42.1	44	6	AX008706	AX008706 Sequence
C	20	12.2	42.1	44	6	AX008707	AX008707 Sequence
C	21	12.2	42.1	69	6	AR052906	AR052906 Sequence
C	22	12.2	42.1	69	6	AR054269	AR054269 Sequence
C	23	12.2	42.1	69	6	AR054471	AR054471 Sequence
C	24	12.2	42.1	70	6	A42881	A42881 Sequence 13
C	25	12.2	42.1	73	6	E02131	E02131 Pseudoknot
C	26	12.2	42.1	24	6	AX291705	AX291705 Sequence
C	27	11.8	40.7	21	6	AR080204	AR080204 Sequence
C	28	11.8	40.7	21	6	AX088729	AX088729 Sequence
C	29	11.8	40.7	21	6	AX088730	AX088730 Sequence
C	30	11.8	40.7	33	10	MDTRVNTK	MDTRVNTK
C	31	11.8	40.7	40	10	MDTRVNTA	MDTRVNTA
C	32	11.8	40.7	46	10	MDTRVNTC	MDTRVNTC
C	33	11.8	40.7	47	6	A82690	A82690 Sequence
C	34	11.8	40.7	47	6	A82705	A82705 Sequence
C	35	11.8	40.7	51	10	MDTRVNTD	MDTRVNTD
C	36	11.8	40.7	68	7	PT7GLJ	PT7GLJ
C	37	11.8	40.7	76	10	MUSG1J	MUSG1J
C	38	11.8	40.7	77	6	AX092950	AX092950 Sequence
C	39	11.8	40.7	77	6	AX092951	AX092951 Sequence
C	40	11.8	40.7	77	6	AX167320	AX167320 Sequence
C	41	11.8	40.7	77	6	AX167321	AX167321 Sequence
C	42	11.8	40.7	82	3	SASHOXW20H	SASHOXW20H
C	43	11.8	40.7	100	5	AF174502	AF174502 Bufo andr
C	44	11.6	40.0	36	6	AR176463	AR176463 Sequence
C	45	11.6	40.0	36	6	AR176468	AR176468 Sequence

ALIGNMENTS

RESULT 1
AF174506/C 100 bp DNA linear VRT 20-APR-2000
LOCUS AF174506
DEFINITION Bufo gargarizans K12-97F001 cytochrome b gene, partial cds;
ACCESSION AF174506
VERSION AF174506.1 GI:7620449
KEYWORDS
SOURCE ORGANISM
Bufo gargarizans.
Mitochondrion Bufo gargarizans
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Amphibia; Batrachia; Anura; Neobatrachia; Bufonidae; Bufonidae;
Bufo.
1 (bases 1 to 100)
REFERENCE
AUTHORS Liu, W., Lathrop, A., Fu, J., Yang, D., and Murphy, R.W.
TITLE Phylogeny of East Asian bufonids inferred from mitochondrial DNA sequences (Anura: Amphibia)
JOURNAL Mol. Phylogenet. Evol. 14 (3), 423-435 (2000)
MEDLINE 20179527
PUBMED 10712847
REFERENCE 2 (bases 1 to 100)
REFERENCE Liu, W., Lathrop, A., Fu, J., and Murphy, R.W.
AUTHORS
TITLE Direct Submission

KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

1 (bases 1 to 100)
Liu, W., Lathrop, A., Fu, J., Yang, D., and Murphy, R.W.
Phylogeny of East Asian bufonids inferred from mitochondrial DNA
sequences (Anura: Amphibia)
Mol. Phylogenet. Evol. 14 (3), 423-435 (2000)

2 (bases 1 to 100)
Liu, W., Lathrop, A., Fu, J., and Murphy, R.W.
Direct Submission
Submitted (26-JUL-1999) CIBC, Royal Ontario Museum, 100 Queen's
Park, Toronto, Ontario M5S 2C6, Canada

1. 100
/organism="Bufo melanostictus"
/organelle="mitochondrion"
/specimen_voucher="KIT-97L202"
/db_xref="taxon:30335"
/country="China: Yunnan, Lunan Co."
/product="cytochrome b"
/codon_start=2
/transl_table=2
/product="cytochrome b"
/protein_id="AAF64633.1"
/db_xref="GI:7620464"
/translation="MIGQLASISFTFIIFIIPLGLTENNRLRN"

BASE COUNT 28 a 29 c 10 g 33 t

ORIGIN

Query Match 45.5%; Score 13.2; DB 5; Length 100;
Best Local Similarity 41.7%; Pred. No. 3.1e+03;
Matches 10; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

QY 4 gauncuunungaaagccnangng 27
1 : ::: |::| | | | |
DB 82 GTTATTTCGTGTAAGTCTGAAG 59

RESULT 5
AF174514/c

DEFINITION
AF174514
AF174514
AF174514.1 GI:7620465

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

100 bp DNA linear VRT 20-APR-2000
Bufo melanostictus K1Z-97L118 cytochrome b gene, partial cds;
mitochondrial gene for mitochondrial product.

REFERENCE
AUTHORS
TITLE
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES

1 (bases 1 to 100)
Liu, W., Lathrop, A., Fu, J., Yang, D., and Murphy, R.W.
Phylogeny of East Asian bufonids inferred from mitochondrial DNA
sequences (Anura: Amphibia)
Mol. Phylogenet. Evol. 14 (3), 423-435 (2000)

2 (bases 1 to 100)
Liu, W., Lathrop, A., Fu, J., and Murphy, R.W.
Direct Submission
Submitted (26-JUL-1999) CIBC, Royal Ontario Museum, 100 Queen's
Park, Toronto, Ontario M5S 2C6, Canada

location/Qualifiers

source

1. 100
/organism="Bufo melanostictus"
/organelle="mitochondrion"
/specimen_voucher="KIT-97L118"
/db_xref="taxon:30335"
/country="China: Yunnan, Mengla Co."
/product="cytochrome b"
/codon_start=2
/transl_table=2
/product="cytochrome b"
/protein_id="AAF64633.1"
/db_xref="GI:7620464"
/translation="MIGQLASISFTFIIFIIPLGLTENNRLRN"

BASE COUNT 28 a 29 c 10 g 33 t

ORIGIN

Query Match 45.5%; Score 13.2; DB 5; Length 100;
Best Local Similarity 41.7%; Pred. No. 3.1e+03;
Matches 10; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

QY 4 gauncuunungaaagccnangng 27
1 : ::: |::| | | | |
DB 82 GTTATTTCGTGTAAGTCTGAAG 59

RESULT 6
AF174515/c

LOCUS
DEFINITION
AF174515
AF174515
AF174515.1 GI:7620467

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

100 bp DNA linear VRT 20-APR-2000
Bufo melanostictus K1Z-92L080 cytochrome b gene, partial cds;
mitochondrial gene for mitochondrial product.

REFERENCE
AUTHORS
TITLE
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES

1 (bases 1 to 100)
Liu, W., Lathrop, A., Fu, J., Yang, D., and Murphy, R.W.
Phylogeny of East Asian bufonids inferred from mitochondrial DNA
sequences (Anura: Amphibia)
Mol. Phylogenet. Evol. 14 (3), 423-435 (2000)

2 (bases 1 to 100)
Liu, W., Lathrop, A., Fu, J., and Murphy, R.W.
Direct Submission
Submitted (26-JUL-1999) CIBC, Royal Ontario Museum, 100 Queen's
Park, Toronto, Ontario M5S 2C6, Canada

location/Qualifiers

1. 100
/organism="Bufo melanostictus"
/organelle="mitochondrion"
/specimen_voucher="KIT-92L080"
/db_xref="taxon:30335"
/country="China: Yunnan, Tengchong Co."
/product="cytochrome b"
/codon_start=2
/transl_table=2
/product="cytochrome b"
/protein_id="AAF64634.1"
/db_xref="GI:7620468"
/translation="MIGQLASISFTFIIFIIPLGLTENNRLRN"

BASE COUNT 28 a 29 c 10 g 33 t

ORIGIN

Query Match 45.5%; Score 13.2; DB 5; Length 100;
Best Local Similarity 41.7%; Pred. No. 3.1e+03;
Matches 10; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

OY 4 gauncununguaagccnang 27
| : : : : | : | | | | | | | |
Db 82 GTTATTTCGTGAGCCCTAAGAG 59

RESULT 7
AF174516/c 100 bp DNA linear VRT 20-APR-2000
LOCUS Bufo melanostictus K12-97L372 cytochrome b gene, partial cds;
DEFINITION mtchondrial gene for mitochondrial product.
ACCESSION AF174516
VERSION AF174516.1 GI:7620469
KEYWORDS
SOURCE Bufo melanostictus.
ORGANISM Mitochondrion Bufo melanostictus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Amphibia; Batrachia; Anura; Neobatrachia; Bufonidae; Bufonidae;
Bufo.
1 (bases 1 to 100)
Liu, W., Lathrop, A., Fu, J., Yang, D. and Murphy, R. W.
Phylogeny of East Asian bufonids inferred from mitochondrial DNA
sequences (Anura: Amphibia)
Mol. Phylogenet. Evol. 14 (3), 423-435 (2000)
PUBMED 10712847
MEDLINE 20179527
JOURNAL 2 (bases 1 to 100)
Liu, W., Lathrop, A., Fu, J. and Murphy, R. W.
Direct Submission
Submitted (26-JUL-1999) CBCB, Royal Ontario Museum, 100 Queen's
Park, Toronto, Ontario M5S 2C6, Canada
Location/Qualifiers
1. 100
/organism="Bufo melanostictus"
/organelle="mitochondrion"
/specimen_voucher="K12-97L372"
/db_xref="taxon:30335"
/country="Taiwan"
<1. >100
/product="cytochrome b"
<1. .100
/codon_start=2
/transl_table=2
/product="cytochrome b"
/protein_id="AF64635.1"
/db_xref="GI:7620470"
/translation="MIGQLASISYFAIFVIFPLDGLTENNILARLN"
BASE COUNT 25 a 30 c 32 t
ORIGIN

FEATURES
1. source

Query Match 45.5%; Score 13.2; DB 5; Length 100;
Best Local Similarity 41.7%; Pred. No. 3.1e+03;
Matches 10; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

OY 4 gauncununguaagccnang 27
| : : : : | : | | | | | | | |
Db 82 GTTATTTCGTGAGCCCTAAGAG 59

RESULT 8
AF174517/c 100 bp DNA linear VRT 20-APR-2000
LOCUS Bufo melanostictus ROM 33162 cytochrome b gene, partial cds;
DEFINITION mtchondrial gene for mitochondrial product.
ACCESSION AF174517
VERSION AF174517.1 GI:7620471
KEYWORDS
SOURCE Bufo melanostictus.
ORGANISM Mitochondrion Bufo melanostictus

REFERENCE 1 (bases 1 to 100)
AUTHORS Liu, W., Lathrop, A., Fu, J., Yang, D. and Murphy, R. W.
TITLE Phylogeny of East Asian bufonids inferred from mitochondrial DNA
sequences (Anura: Amphibia)
JOURNAL Mol. Phylogenet. Evol. 14 (3), 423-435 (2000)
MEDLINE 20179527
PUBMED 10712847
REFERENCE 2 (bases 1 to 100)
AUTHORS Liu, W., Lathrop, A., Fu, J. and Murphy, R. W.
TITLE Direct Submission
JOURNAL Submitted (26-JUL-1999) CBCB, Royal Ontario Museum, 100 Queen's
Park, Toronto, Ontario M5S 2C6, Canada
Location/Qualifiers
1. 100
/organism="Bufo melanostictus"
/organelle="mitochondrion"
/specimen_voucher="ROM 33162"
/db_xref="taxon:30335"
/country="Viet Nam: Gia Lai, Ko Rong"
<1. >100
/product="cytochrome b"
<1. .100
/codon_start=2
/transl_table=2
/product="cytochrome b"
/protein_id="AF64636.1"
/db_xref="GI:7620472"
/translation="MIGQLASISYFAIFVIFPLDGLTENNILARLN"
BASE COUNT 25 a 30 c 32 t
ORIGIN

FEATURES
1. source

Query Match 45.5%; Score 13.2; DB 5; Length 100;
Best Local Similarity 41.7%; Pred. No. 3.1e+03;
Matches 10; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

OY 4 gauncununguaagccnang 27
| : : : : | : | | | | | | | |
Db 82 GTTATTTCGTGAGCCCTAAGAG 59

RESULT 9
AF174518/c 100 bp DNA linear VRT 20-APR-2000
LOCUS Bufo melanostictus ROM 32540 cytochrome b gene, partial cds;
DEFINITION mtchondrial gene for mitochondrial product.
ACCESSION AF174518
VERSION AF174518.1 GI:7620473
KEYWORDS
SOURCE Bufo melanostictus.
ORGANISM Mitochondrion Bufo melanostictus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Amphibia; Batrachia; Anura; Neobatrachia; Bufonidae; Bufonidae;
Bufo.
1 (bases 1 to 100)
Liu, W., Lathrop, A., Fu, J., Yang, D. and Murphy, R. W.
Phylogeny of East Asian bufonids inferred from mitochondrial DNA
sequences (Anura: Amphibia)
Mol. Phylogenet. Evol. 14 (3), 423-435 (2000)
PUBMED 10712847
MEDLINE 20179527
JOURNAL 2 (bases 1 to 100)
Liu, W., Lathrop, A., Fu, J. and Murphy, R. W.
Direct Submission
Submitted (26-JUL-1999) CBCB, Royal Ontario Museum, 100 Queen's
Park, Toronto, Ontario M5S 2C6, Canada
Location/Qualifiers
1. 100
/organism="Bufo melanostictus"
/organelle="mitochondrion"

QY 4 gauncununguaagccnang 27
| : : : | : | | | | | | |
Db 82 GTTGTCTTCTGTGAGCCCTAAG 59

RESULT 11
AF174520/c 100 bp DNA linear VRT 20-APR-2000
LOCUS Bufo melanostictus ROM 33855 cytochrome b gene, partial cds;
DEFINITION mitochondrial gene for mitochondrial product.
ACCESSION AF174520
VERSION AF174520.1 GI:7620477
KEYWORDS
SOURCE
ORGANISM Bufo melanostictus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Amphibia; Batrachia; Anura; Neobatrachia; Bufonidae; Bufonidae;
Bufo.

REFERENCE 1 (bases 1 to 100)
AUTHORS Liu, W., Lathrop, A., Fu, J., Yang, D. and Murphy, R.W.
TITLE Phylogeny of East Asian bufonids inferred from mitochondrial DNA
JOURNAL Mol. Phylogenet. Evol. 14 (3), 423-435 (2000)
MEDLINE 20179527
PUBMED 10712847
REFERENCE 2 (bases 1 to 100)
AUTHORS Liu, W., Lathrop, A., Fu, J. and Murphy, R.W.
TITLE Direct Submission
JOURNAL Submitted (26-JUL-1999) CIBC, Royal Ontario Museum, 100 Queen's
Park, Toronto, Ontario M5S 2C6, Canada

FEATURES
source
1..100
/organism="Bufo melanostictus"
/organelle="mitochondrion"
/specimen_voucher="ROM 33855"
/db_xref="taxon:30335"
/country="Viet Nam: Dac Lac, Yok Don"
/product="cytochrome b"
/codon_start=2
/transl_table=2
/product="cytochrome b"
/protein_id="AA64639.1"
/db_xref="GI:7620478"
/translation="MIGQLASISYFAIFVIFPLGLTENNILRLN"

BASE COUNT 25 a 30 c 13 g 32 t

ORIGIN

Query Match 45.5%; Score 13.2; DB 5; Length 100;
Best Local Similarity 41.7%; Pred. No. 3.1e+03;
Matches 10; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

QY 4 gauncununguaagccnang 27
| : : : | : | | | | | | |
Db 82 GTTGTCTTCTGTGAGCCCTAAG 59

RESULT 12
AF174521/c 100 bp DNA linear VRT 20-APR-2000
LOCUS Bufo melanostictus ROM 33861 cytochrome b gene, partial cds;
DEFINITION mitochondrial gene for mitochondrial product.
ACCESSION AF174521
VERSION AF174521.1 GI:7620479
KEYWORDS
SOURCE
ORGANISM Bufo melanostictus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Amphibia; Batrachia; Anura; Neobatrachia; Bufonidae; Bufonidae;
Bufo.

REFERENCE 1 (bases 1 to 100)
AUTHORS Liu, W., Lathrop, A., Fu, J., Yang, D. and Murphy, R.W.
TITLE Phylogeny of East Asian bufonids inferred from mitochondrial DNA
JOURNAL Mol. Phylogenet. Evol. 14 (3), 423-435 (2000)
MEDLINE 20179527
PUBMED 10712847
REFERENCE 2 (bases 1 to 100)
AUTHORS Liu, W., Lathrop, A., Fu, J. and Murphy, R.W.
TITLE Direct Submission
JOURNAL Submitted (26-JUL-1999) CIBC, Royal Ontario Museum, 100 Queen's
Park, Toronto, Ontario M5S 2C6, Canada

FEATURES
source
1..100
/organism="Bufo melanostictus"
/organelle="mitochondrion"
/specimen_voucher="ROM 33855"
/db_xref="taxon:30335"
/country="Viet Nam: Dac Lac, Yok Don"
/product="cytochrome b"
/codon_start=2
/transl_table=2
/product="cytochrome b"
/protein_id="AA64639.1"
/db_xref="GI:7620478"
/translation="MIGQLASISYFAIFVIFPLGLTENNILRLN"

BASE COUNT 25 a 30 c 13 g 32 t

ORIGIN

Query Match 45.5%; Score 13.2; DB 5; Length 100;
Best Local Similarity 41.7%; Pred. No. 3.1e+03;
Matches 10; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

```

REFERENCE 1 (bases 1 to 100)
AUTHORS Liu, W., Lathrop, A., Fu, J., Yang, D. and Murphy, R. W.
TITLE Phylogeny of East Asian bufonids inferred from mitochondrial DNA
        sequences (Anura: Amphibia)
JOURNAL Mol. Phylogenet. Evol. 14 (3), 423-435 (2000)
MEDLINE 10712847
PUBMED 2 (bases 1 to 100)
REFERENCE Liu, W., Lathrop, A., Fu, J. and Murphy, R. W.
AUTHORS Direct Submission
TITLE Submitted (26-JUL-1999) CBCB, Royal Ontario Museum, 100 Queen's
JOURNAL Park, Toronto, Ontario M5S 2C6, Canada
FEATURES
    source
        1. 100
            /organism="Bufo melanostictus"
            /organella="mitochondrion"
            /specimen_voucher="ROM 33861"
            /db_xref="taxon:30335"
            /country="Viet Nam: Dac Lac, Yok Don"
            <1. >100
            /product="cytochrome b"
            <1. 100
            /codon_start=2
            /transl_table=2
            /product="cytochrome b"
            /protein_id="AF64640.1"
            /db_xref="GI:7620480"
            /translation="MIGQLASISYFAIFIVIFPLGLTENNLRNLN"
BASE COUNT 25 a 30 c 13 g 32 t
ORIGIN

Query Match 45.5%; Score 13.2; DB 5; Length 100;
Best Local Similarity 41.7%; Pred. No. 3.1e+03;
Matches 10; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

QY 4 gauncuunguaagccnang 27
    1 : :: : | | | | | | |
    Db 82 GTTGTTTCTGTGAGCCCTAGAG 59

RESULT 13
AF144669/c 82 bp DNA linear INV 04-AUG-1999
LOCUS
DEFINITION Patella vulgata antennapedia-like homeodomain protein HB3 gene,
ACCESSION AF144669
VERSION AF144669.1 GI:5690267
WORDS
SOURCE common limpet.
ORGANISM Patella vulgata
Eukaryota; Metazoa; Mollusca; Gastropoda; Archaeogastropoda;
Patelloidea; Patellidae; Patella.
REFERENCE 1 (bases 1 to 82)
AUTHORS de Rosa, R., Grenier, J. K., Andreeva, T., Cook, C. E., Adoutte, A.,
        Alam, M., Carroll, S. B. and Balavoine, G.
TITLE Hox genes in brachiopods and priapulids and protostome evolution
JOURNAL Nature 399 (6738), 772-776 (1999)
MEDLINE 99318125
PUBMED 2 (bases 1 to 82)
REFERENCE de Rosa, R., Lartillot, N. and Adoutte, A.
AUTHORS Direct Submission
TITLE Submitted (21-APR-1999) Centre de Genetique Moleculaire, Avenue de
JOURNAL la Terrasse, Gif-sur-Yvette 91198, France
FEATURES
    source
        1. 82
            /organism="Patella vulgata"
            /db_xref="taxon:6465"
            <1. >82
            /product="antennapedia-like homeodomain protein HB3"
            <1. >82
            /codon_start=2

```

```

BASE COUNT 34 a 16 c 17 g 15 t
ORIGIN

Query Match 44.8%; Score 13; DB 3; Length 82;
Best Local Similarity 56.2%; Pred. No. 4.1e+03;
Matches 9; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 8 cuununguaagccca 23
    1 : : | | | | | |
    Db 69 CTTCTGTGAACCCGA 54

RESULT 14
MDTRVNB/c 53 bp mRNA linear ROD 07-MAR-1993
LOCUS M.domesticus DBA/2 rearranged T-cell receptor (Vgamma2-N-Jgamma2).
DEFINITION X63580
ACCESSION X63580.1 GI:57892
VERSION
KEYWORDS joining region; N-region; T-cell receptor; variable region.
SOURCE western European house mouse.
ORGANISM Mus musculus domesticus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 53)
AUTHORS Roger, T. R.
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 53)
AUTHORS Roger, T.
TITLE Direct Submission
JOURNAL Submitted (16-DEC-1991) T. Roger, Laboratoire
        d'Immunodifferentiation, Service du Pr SEBAN, Institut J. MONOD, 2,
        Place JUSSIEU, 75251 PARIS CEDEX 05, FRANCE
FEATURES
    source
        1. 53
            /organism="Mus musculus domesticus"
            /strain="DBA/2"
            /db_xref="taxon:10092"
            /chromosome="13"
            /dev_stage="Seed, cell expansion stage"
            /tissue_type="Spleen"
            /cell_type="CD4- CD8- T lymphocyte clone"
            /cell_line="1G3"
            /clone_11b="library lambda gtl1"
            /clone="1G3gamma5"
            1. 24
            /product="End of the T-cell receptor Vgamma2 gene
            segment"
            misc_feature 25..31
            misc_feature /product="N Sequence"
            misc_feature 32..53
            /product="Beginning of the T cell receptor Jgamma2 gene
            segment"
BASE COUNT 10 a 15 c 11 g 17 t
ORIGIN

Query Match 44.1%; Score 12.8; DB 10; Length 53;
Best Local Similarity 52.4%; Pred. No. 5.3e+03;
Matches 11; Conservative 3; Mismatches 7; Indels 0; Gaps 0;

QY 5 auncuunguaagccnang 25
    1 : : | | | | | |
    Db 51 ATACCTGTGAAGCCGAG 31

RESULT 15
AF174501/c 100 bp DNA linear VRT 20-APR-2000
LOCUS

```



```

DEFINITION Bufo himalayanus K12-95L010 cytochrome b gene, partial cds;
ACCESSION AF174501
VERSION AF174501.1 GI:7620439
KEYWORDS
SOURCE
ORGANISM Bufo himalayanus.
            Mitochondrion Bufo himalayanus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Amphibia; Batrachia; Anura; Neobatrachia; Bufonidae; Bufonidae;
            Bufo.
REFERENCE 1 (bases 1 to 100)
AUTHORS Liu,W., Lathrop,A., Fu,J., Yang,D. and Murphy,R.W.
TITLE Phylogeny of East Asian bufonids inferred from mitochondrial DNA
        sequences (Anura: Amphibia)
JOURNAL Mol. Phylogenet. Evol. 14 (3), 423-435 (2000)
MEDLINE 20179527
PUBMED 10712847
REFERENCE 2 (bases 1 to 100)
AUTHORS Liu,W., Lathrop,A., Fu,J. and Murphy,R.W.
TITLE Direct Submission
JOURNAL Submitted (26-JUL-1999) CBCB, Royal Ontario Museum, 100 Queen's
        Park, Toronto, Ontario M5S 2C6, Canada
FEATURES
            Location/Qualifiers
            1..100
                /organism="Bufo himalayanus"
                /organelle="mitochondrion"
                /specimen_voucher="K12-95L010"
                /db_xref="taxon:103434"
                /country="China: Yunnan, Gongsan Co."
                <1..>100
                /product="cytochrome b"
                <1..100
                /codon_start=2
                /transl_table=2
                /product="cytochrome b"
                /protein_id="AAF64620.1"
                /db_xref="GI:7620440"
                /translation="MIGOLASISYFTPIIPILPLGLTENKRLRLN"
            BASE COUNT      28 a      31 c      11 g      30 t
            ORIGIN
Query Match      44.1%; Score 12.8; DB 5; Length 100;
Best Local Similarity 40.9%; Pred. No. 5.6e+03;
Matches 9; Conservative 5; Mismatches 8; Indels 0; Gaps 0;
QY      6 uncuununguaagcccnang 27
      :   :   :   :   :   :   :
      80 TGTTCCTGTCAGCCCTAGAG 59

```

Search completed: April 29, 2002, 22:07:08
 Job time: 14216 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 29, 2002, 21:37:54 ; Search time 310.59 Seconds
(without alignments)
160.309 Million cell updates/sec

Title: US-09-310-844C-23

Perfect score: 29

Sequence: 1 nnnnauuncuunnguaagcccnangnngn 29

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues 2046006

Minimum DB seq length: 0
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

N.Geneseq_012802:*

- 1: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA1980.DAT:*
- 2: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA1981.DAT:*
- 3: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA1982.DAT:*
- 4: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA1983.DAT:*
- 5: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA1984.DAT:*
- 6: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA1985.DAT:*
- 7: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA1986.DAT:*
- 8: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA1987.DAT:*
- 9: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA1988.DAT:*
- 10: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA1989.DAT:*
- 11: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA1990.DAT:*
- 12: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA1991.DAT:*
- 13: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA1992.DAT:*
- 14: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA1993.DAT:*
- 15: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA1994.DAT:*
- 16: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA1995.DAT:*
- 17: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA1996.DAT:*
- 18: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA1997.DAT:*
- 19: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA1998.DAT:*
- 20: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA1999.DAT:*
- 21: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA2000.DAT:*
- 22: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA2001A.DAT:*
- 23: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA2001B.DAT:*
- 24: /net/abs06/SIDSL/gcgdata/hold-geneseq/geneseqn-emb1/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	18	62.1	29	21	AAA70827
2	18	62.1	29	21	AAA70828
3	18	62.1	29	21	AAA70829
4	18	62.1	29	21	AAA70830
5	18	62.1	42	21	AAA71113
6	18	62.1	42	21	AAA71114
7	18	62.1	42	21	AAA71115
8	18	62.1	42	21	AAA71116
9	18	62.1	42	21	AAA71118

10	18	62.1	42	21	AAA71119	Molecular interact
11	18	62.1	42	21	AAA71120	Molecular interact
12	18	62.1	42	21	AAA71121	Molecular interact
13	18	62.1	42	21	AAA71123	Molecular interact
14	18	62.1	42	21	AAA71124	Molecular interact
15	18	62.1	42	21	AAA71126	Molecular interact
16	18	62.1	42	21	AAA71127	Molecular interact
17	18	62.1	42	21	AAA71128	Molecular interact
18	18	62.1	42	21	AAA71129	Molecular interact
19	18	62.1	42	21	AAA71131	Molecular interact
20	18	62.1	42	21	AAA71132	Molecular interact
21	18	62.1	44	21	AAA71112	Molecular interact
22	18	62.1	44	21	AAA71125	Molecular interact
23	18	62.1	44	21	AAA71133	Molecular interact
24	18	62.1	45	21	AAA70824	Molecular interact
25	18	62.1	45	21	AAA70825	Molecular interact
26	18	62.1	45	21	AAA70826	Molecular interact
27	18	62.1	46	21	AAA71085	Molecular interact
28	18	62.1	46	21	AAA71087	Molecular interact
29	18	62.1	46	21	AAA71088	Molecular interact
30	18	62.1	46	21	AAA71089	Molecular interact
31	18	62.1	46	21	AAA71090	Molecular interact
32	18	62.1	46	21	AAA71093	Molecular interact
33	18	62.1	46	21	AAA71094	Molecular interact
34	18	62.1	46	21	AAA71095	Molecular interact
35	18	62.1	46	21	AAA71096	Molecular interact
36	18	62.1	46	21	AAA71099	Molecular interact
37	18	62.1	46	21	AAA71100	Molecular interact
38	18	62.1	46	21	AAA71103	Molecular interact
39	18	62.1	46	21	AAA71104	Molecular interact
40	18	62.1	46	21	AAA71105	Molecular interact
41	18	62.1	46	21	AAA71106	Molecular interact
42	18	62.1	46	21	AAA71107	Molecular interact
43	18	62.1	46	21	AAA71109	Molecular interact
44	18	62.1	46	21	AAA71110	Molecular interact
45	18	62.1	46	21	AAA71111	Molecular interact

ALIGNMENTS

RESULT 1
ID AAA70827 standard: RNA; 29 BP.
XX AAA70827;
AC 27-APR-2001 (first entry)
DF 27-APR-2001 (first entry)
XX DE Molecular interaction site RNA #27.
XX KW Modulator; identification; molecular interaction; virtual library; ss.
XX OS Synthetic.
XX PN WO958947-A2.
XX PD 18-NOV-1999.
XX PR 12-MAY-1999; 99WO-US10361.
XX PR 12-MAY-1998; 98US-0076404.
XX PR 12-MAY-1998; 98US-0065092.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
XX PI Hostadler S, McNeill J;
XX WP1: 2000-086439/07.
XX PT Identifying compounds which modulate activity of target biomolecules,
XX PT used to provide compounds which can be used as pharmacological,

XX agricultural and industrial compounds -
PS Claim 235; Page 235; 405pp; English.
XX
XX This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA complisting
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACAAUACUAGUUUACGAAUAAC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
XX Sequence 29 BP; 4 A; 4 C; 5 G; 5 U; 11 other;
XX

Query March 62.1%; score 18; DB 21; length 29;
Best Local Similarity 100.0%; Pred. NO. 0.97;
Matches 24; Conservative 0; Mismatches 0; Gaps 0;

Qy	4	gauncuunguaagcccnangng	27
Db	4	gauncuunguaagcccnangng	27

RESULT	2
AAA70828	
ID	AAA70828 standard; RNA; 29 BP
XX	
AC	AAA70828;

27-APR-2001 (first entry)

DE Molecular interaction site RNA #28.

KW Modulator; identification; molecular interaction; virtual library; ss.

OS. Homo sapiens.

PN W09958947-A2

PD 18-NOV-1999.

PF 12-MAY-1999;

PR 12-MAY-1998;

XX

XX

PI Hofstadler S, McNeil J

DR WPI; 2000-086439/07.

PT Identifying compounds which modulate activity of target biomolecules,

PT. used to provide compounds which can be used as pharmacological,

PT	agricultural and industrial compounds -
XX	
PS	Claim 235; Page 235; 405pp; English.

CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating *in silico* a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACUAAUUCAGUUGUACGAAAAUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.

SQ Sequence 29 BP; 5 A; 5 C; 7 G; 12 U; 0 other;

Query Match	62.1%	Score 18:	DB 21:	Length 29:
Best Local Similarity	75.0%	Pred. No.	0.97:	
Matches 18:	Conservative	0:	Mismatches 6:	Indels 0:
				Gaps 0:

Qy 4 gauncuunguaagcccnangng 27
||| ||| ||| ||| | |
Db 4 gauncuunguaagcccnangng 27

RESULT	3
AAA70829	
ID	AAA70829 standard; RNA; 29 BP

AC AAA70829;

DT 27-APR-2001 (first entry)

DE Molecular interaction site RNA #29.

KW Modulator; identification; molecular interaction; virtual library; ss.

Mus sp.

PN WO9958947-A2

PD 18-NOV-1999

PF 12-MAY-1999;

PR 12-MAY-1998; 98US-0076404.

[illegible]

XX
XX

PI Hofstadler S, McNeil J

DR WPI; 2000-086439/07.

PT Identifying compounds which modulate activity of target biomolecules,

PT used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
XX
XX Claim 235; Page 235; 405pp; English.
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACAUUAUCGAGUUAACGAAAAUC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
SQ Sequence 29 BP; 8 A; 6 C; 6 G; 9 U; 0 other;

Query Match 62.1%; Score 18; DB 21; Length 29;
Best Local Similarity 75.0%; Pred. No. 0.97;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 4 gauncuununguaagcccnangng 27
||| |||| |||| |||| |||
Db 4 gauncuununguaagccccaaggg 27

RESULT 4
ID AAA70830 standard; RNA; 29 BP.
XX
XX AAA70830;

AC 27-APR-2001 (first entry)
XX
XX

DT Molecular interaction site RNA #30.

KM Modulator; identification; molecular interaction; virtual library; ss.

OS Rattus sp.

PN WO9558947-A2.

PD 18-NOV-1999.

PF 12-MAY-1999; 99WO-US10361.

PR 12-MAY-1998; 98US-0076404.

PR 12-MAY-1998; 98US-0085092.

XX (ISIS-) ISIS PHARM INC.

PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
XX Hofstadler S, McNeil J;

DR WPI; 2000-086439/07.

PT Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
XX
XX Claim 235; Page 235; 405pp; English.
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACAUUAUCGAGUUAACGAAAAUC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
SQ Sequence 29 BP; 8 A; 6 C; 6 G; 9 U; 0 other;

Query Match 62.1%; Score 18; DB 21; Length 29;
Best Local Similarity 75.0%; Pred. No. 0.97;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 4 gauncuununguaagcccnangng 27
||| |||| |||| |||| |||
Db 4 gauncuununguaagccccaaggg 27

RESULT 5
ID AAA71113 standard; RNA; 42 BP.
XX
XX AAA71113;

AC 27-APR-2001 (first entry)
XX
XX

DT Molecular interaction site RNA #189.

KM Modulator; identification; molecular interaction; virtual library; ss.

OS unidentified.

PN WO9558947-A2.

PD 18-NOV-1999.

PF 12-MAY-1999; 99WO-US10361.

PR 12-MAY-1998; 98US-0076404.

PR 12-MAY-1998; 98US-0085092.

XX (ISIS-) ISIS PHARM INC.

PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
XX Hofstadler S, McNeil J;

DR WPI; 2000-086439/07.

PT Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,

PT · agricultural and industrial compounds
XX
PS Example 7; Figure 122; 405pp; English..

This invention describes a novel method for identifying compounds which modulate the activity of a target biomolecule. The method uses 3-dimensional representations of the biomolecule and a library of compounds and comprises (a) identifying at least one molecular interaction site of the target RNA; (b) generating in silico a virtual library of compounds predicted or calculated to interact with the molecular interaction site; and (c) comparing 3-dimensional (3-D) representations of the target RNA with members of the virtual library of compounds to generate a hierarchy of the compounds ranked in accordance with their respective ability to form physical interactions with the molecular interaction site. The method also describes (1) RNA comprising a joined sequence of at least 24 nucleotides but not more than 70 nucleotides and having secondary structure defined by: (a) 3 nucleotides forming a first side of a first double stranded (ds) region; (b) 2 nucleotides forming a first side of an internal loop region; (c) 4 nucleotides forming a first side of a second ds region; (d) 4 or 5 nucleotides forming an end loop region; (e) 4 nucleotides forming a second side of the second ds region; and (f) 3 nucleotides forming a second side of the internal loop region; and (g) 3 nucleotides forming a second side of the first ds region; (2) a purified and isolated RNA fragment comprising the human sequence UUUUACUUAUUCUUGUUGUUGAGAAUAAC (II). The methods and products can be used for identifying agents which modulate the activity of biomolecules, particularly RNA. Such agents can be used as pharmaceutical, agricultural or industrial compounds.

Query Match	62.1%	Score 18;	DB 21;	Length 42;
Best Local Similarity	75.0%	Pred. No. 1;		
Matches 18; Conservative	0;	Mismatches 6;	Indels 0;	Gaps 0

Qy 4 gauncuuunguaagcccnangng 27
||| ||| ||| ||| | | |
Db 7 gaucuuuunguaagcccuaggg 30

RESULT	6
AAA71114	
ID	AAA71114 standard; RNA; 42 BP

27-APR-2001 (first entry)

DE Molecular interaction site RNA #190.

KW Modulator; identification; molecular interaction; virtual library; ss

OS Unidentified

PN W09958947-A2

PD 18-NOV-1999.

PF 12-MAY-1999; 99WO-US10361.

PR 12-MAY-1998; 98US-0076404.

PR 12-MAY-1998; 98US-0085092.

PA (ISIS-) ISIS PHARM INC.

XX
XX

PI Hofstadler S, McNeill J;

DR WPI; 2000-086439/07.

PT Identifying compounds which modulate activity of target biomolecules
PI used to provide compounds which can be used as pharmacological,

PT	agricultural and industrial compounds
XX	
PS	Example 7; Figure 122; 405pp; English..

CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming an end loop region; (d) 4 or 5
CC nucleotides forming a second side of a second ds region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACAAUUAUUCUGUUUACGAAAAAC (ii). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.

Query Match	62.1%	Score 18:	DB 21:	Length 42:
Best Local Similarity	75.0%	Pred. No. 1:		
Matches 18; Conservative	0;	Mismatches	6;	Indels 0; Gaps 0

DY 4 gauncuuunnguagcccnang 27
 | | | | | | | | | |
Db 7 gaucuuuuuguaagcccuagcg 30

RESULT	7
AAA71115	
ID	AAA71115 standard; RNA; 42 BP

DT 27-APR-2001 (first entry)

DE Molecular interaction site RNA #191.

KW Modulator; identification; molecular interaction; virtual library; ss

OS Unidentified

PN W09958947-A2

PD 18-NOV-1999

PF 12-MAY-1999; 99WO-US10361.

PR 12-MAY-1998; 98US-0076404.

PR 12-MAY-1998; 98US-0085092.

PA (ISIS-) ISIS PHARM INC.

XX

PI Hofstadler S, McNeil J;

DR WPI; 2000-086439/07

PT Identifying compounds which modulate activity of target biomolecules
PT used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
XX
XX
XX Example 7; Figure 125; 405bp; English.
CC
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACUAUUAUCGUGUACGAAAUUC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
XX Sequence 42 BP; 12 A; 7 C; 6 G; 17 T; 0 other;
50

Query Match	62.1%	Score 18;	DB 21;	Length 42;
Best Local Similarity	54.2%;	Pred. No. 1;		
Matches 13; Conservative	5;	Mismatches 6;	Indels 0;	Gaps 0;

Qy 4 gauncuunguaagcccnangy 27
11::1111111111
Db 7 gattccttgytaagccctacgy 30

```

RESULT 10
AAA71119
ID AAA71119 standard; DNA; 42 BP
XX
AC AAA71119;

```

27-APR-2001 (first entry)

DE Molecular interaction site DNA #125.

KW Modulator; identification; molecular interaction; virtual library; ss.

OS Unidentified

PN W09958947-A2

PD 18-NOV-1999.

PF 12-MAY-1999;

PR 12-MAY-1998; 98US-0076404.

XX

XX

PI Hofstadler S, McNeil J;

DR WPI; 2000-086439/07.

PT Identifying compounds which modulate activity of target biomolecules, used to provide compounds which can be used as pharmacological,

PT	agricultural and industrial compounds
XX	
PS	Example 7; Figure 125; 405pp; English.

This invention describes a novel method for identifying compounds which modulate the activity of a target biomolecule. The method uses 3-dimensional representations of the biomolecule and a library of compounds and comprises (a) identifying at least one molecular interaction site of the target RNA; (b) generating in silico a virtual library of compounds predicted or calculated to interact with the molecular interaction site; and (c) comparing 3-dimensional (3-D) representations of the target RNA with members of the virtual library of compounds to generate a hierarchy of the compounds ranked in accordance with their respective ability to form physical interactions with the molecular interaction site. The method also describes (1) RNA comprising a joined sequence of at least 24 nucleotides but not more than 70 nucleotides and having secondary structure defined by: (a) 3 nucleotides forming a first side of a first double stranded (ds) region; (b) 2 nucleotides forming a first side of an internal loop region; (c) 4 nucleotides forming a first side of a second ds region; (d) 4 or 5 nucleotides forming an end loop region; (e) 4 nucleotides forming a second side of the second ds region; (f) 4 nucleotides forming a second side of the internal loop region; and (g) 3 nucleotides forming a second side of the first ds region; (2) a purified and isolated RNA fragment comprising the human sequence UUUUACGACUAUUCUAGUUAAGAAUAG (II). The methods and products can be used for identifying agents which modulate the activity of biomolecules, particularly RNA. Such agents can be used as pharmaceutical, agricultural or industrial compounds.

Sequence 42 BP; 11 A; 8 C; 7 G; 16 T; 0 other;

Query Match	62.1%;	Score 18;	DB 21;	Length 42;
Best Local Similarity	54.2%;	Pred. No. 1;		
Matches 13; Conservative		5; Mismatches	6; Indels	0; Gaps

QY 4 gauncuunguaagcccnangng 27
||:|::|:||||| | | |
Db 7 gattcctttgtlaagccctlagcg 30

RESULT	11
AAA71120	
ID	AAA71120 standard; DNA; 42 BP

AAA71120;

DT 27-APR-2001 (first entry)

DE Molecular interaction site DNA #126.

KW Modulator; identification; molecular interaction; virtual library; ss.

Unidentified OS

PN W09958947-A2

PD 18-NOV-1999.

PF 12-MAY-1999;

PR 12-MAY-1998; 98US-0076404.

XX
XX

XX

PI Hofstadler S, McNeil J;

DR WPI; 2000-086439/07.

PT Identifying compounds which modulate activity of target biomolecules
PT used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
XX
XX
PS Example 7; Figure 125; 405pp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACAUAAUUCUUAUACAGAAAUUC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
SQ Sequence 42 BP; 13 A; 7 C; 7 G; 15 T; 0 other;
XX
Query Match 62.1%; Score 18; DB 21; Length 42;
Best Local Similarity 54.2%; Pred. No. 1;
Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;
OY 4 gauncuununguaagcccgangng 27
||:|::|:||||| | | |
DB 7 gatctctttgtgaagcccaagg 30
XX
RESULT 12
AAA71121
ID AAA71121 standard; DNA; 42 BP.
XX
AC AAA71121;
XX
DT 27-APR-2001 (first entry)
XX
DE Molecular interaction site DNA #127.
XX
KM Modulator; identification; molecular interaction; virtual library; ss.
XX
OS Unidentified.
XX
PN WO958947-A2.
XX
PD 18-NOV-1999.
XX
PF 12-MAY-1999; 99WO-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
XX
PR 12-MAY-1998; 98US-0085092.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey R, Crooke SF, Sampath R, Swayze E, Mohan V;
XX
PI Hofstadler S, McNeill J;
XX
DR WPI; 2000-086439/07.
XX
PT Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
XX
XX
PS Example 7; Figure 125; 405pp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACAUAAUUCUUAUACAGAAAUUC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
SQ Sequence 42 BP; 13 A; 7 C; 7 G; 15 T; 0 other;
XX
Query Match 62.1%; Score 18; DB 21; Length 42;
Best Local Similarity 54.2%; Pred. No. 1;
Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;
OY 4 gauncuununguaagcccgangng 27
||:|::|:||||| | | |
DB 7 gatctctttgtgaagcccaagg 30
XX
RESULT 13
AAA71123
ID AAA71123 standard; DNA; 42 BP.
XX
AC AAA71123;
XX
DT 27-APR-2001 (first entry)
XX
DE Molecular interaction site DNA #129.
XX
KM Modulator; identification; molecular interaction; virtual library; ss.
XX
OS Unidentified.
XX
PN WO958947-A2.
XX
PD 18-NOV-1999.
XX
PF 12-MAY-1999; 99WO-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
XX
PR 12-MAY-1998; 98US-0085092.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey R, Crooke SF, Sampath R, Swayze E, Mohan V;
XX
PI Hofstadler S, McNeill J;
XX
DR WPI; 2000-086439/07.
XX
PT Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
XX
PS Example 7; Figure 125; 405pp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4 or 5
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACAUACUUGUUCAGAAAUUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
SQ Sequence 42 BP; 9 A; 6 C; 9 G; 18 T; 0 other;

Query Match 62.1%; Score 18; DB 21; Length 42;
Best Local Similarity 54.2%; Pred. No. 1;
Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

QY 4 gauncuununguagccnangng 27
||:|:::|:||||| | | |
Db 7 gatcttcttgtaagcctcaggg 30

RESULT 14
AAA71124
ID AAA71124 standard; DNA: 42 BP.
XX
AC AAA71124;

27-APR-2001 (first entry)

DE Molecular interaction site DNA #130.
XX
KM Modulator; identification; molecular interaction; virtual library; ss.
XX
OS Unidentified.
XX
PN W09958947-A2.
XX
PD 18-NOV-1999.
XX
PE 12-MAY-1999; 99WC-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
XX
PR 12-MAY-1998; 98US-0085092.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
PI Hofstadler S, McNeil J;
XX
DR WPI; 2000-086439/07.
XX
PT Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological.

PT agricultural and industrial compounds -
XX
PS Example 7; Figure 125; 405pp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4 or 5
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACAUACUUGUUCAGAAAUUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
SQ Sequence 42 BP; 11 A; 10 C; 7 G; 14 T; 0 other;

Query Match 62.1%; Score 18; DB 21; Length 42;
Best Local Similarity 54.2%; Pred. No. 1;
Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

QY 4 gauncuununguagccnangng 27
||:|:::|:||||| | | |
Db 7 gatcttcttgtaagcctcaggg 30

RESULT 15
AAA71126
ID AAA71126 standard; RNA: 42 BP.
XX
AC AAA71126;
XX
DT 27-APR-2001 (first entry)
XX
DE Molecular interaction site RNA #195.
XX
KM Modulator; identification; molecular interaction; virtual library; ss.
XX
OS Unidentified.
XX
PN W09958947-A2.
XX
PD 18-NOV-1999.
XX
PE 12-MAY-1999; 99WC-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
XX
PR 12-MAY-1998; 98US-0085092.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
PI Hofstadler S, McNeil J;
XX
DR WPI; 2000-086439/07.
XX
PT Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological.

PT agricultural and industrial compounds -
XX
PS Example 7; Figure 126; 405pp; English.

This invention describes a novel method for identifying compounds which modulate the activity of a target biomolecule. The method uses 3-dimensional representations of the biomolecule and a library of compounds and comprises (a) identifying at least one molecular interaction site of the target RNA; (b) generating *in silico* a virtual library of compounds predicted or calculated to interact with the molecular interaction site; and (c) comparing 3-dimensional (3-D) representations of the target RNA with members of the virtual library of compounds to generate a hierarchy of the compounds ranked in accordance with their respective ability to form physical interactions with the molecular interaction site. The method also describes (1) RNA comprising a joined sequence of at least 24 nucleotides but not more than 70 nucleotides and having secondary structure defined by: (a) 3 nucleotides forming a first side of a first double stranded (ds) region; (b) 2 nucleotides forming a first side of an internal loop region; (c) 4 nucleotides forming a first side of a second ds region; (d) 4 or 5 nucleotides forming an end loop region; (e) 4 nucleotides forming a second side of the second ds region; (f) 4 nucleotides forming a second side of the internal loop region; and (g) 3 nucleotides forming a second side of the first ds region; (2) a purified and isolated RNA fragment comprising the human sequence UUUACACUAUAUCUUAUGACGAAAUUC (11). The methods and products can be used for identifying agents which modulate the activity of biomolecules, particularly RNA. Such agents can be used as pharmaceutical, agricultural or industrial compounds.

Query Match	62.1%	Score 18	DB 21	Length 42
Best Local Similarity	75.0%	Pred. No. 1		
Matches 18	Conservative	0	Mismatches 6	Indels 0
4	gauncuununguaagcccnang	27		
Db	7	gauncuununguaagcccnacg	30	

Search completed: April 29, 2002, 22:45:09
Job time: 4035 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 29, 2002, 19:50:29 ; Search time 60.62 Seconds
(without alignments)
117.509 Million cell updates/sec

Title: US-09-310-844C-23
Perfect score: 29
Sequence: 1 nngauunuuuuaagccnangnn 29

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 383533 seqs, 122816752 residues

Total number of hits satisfying chosen parameters: 613726

Minimum DB seq length: 0
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

Issued_Patents_NA:*
1: /cgn2_6/prodata/1/ina/5A_COMB.seq:*
2: /cgn2_6/prodata/1/ina/5B_COMB.seq:*
3: /cgn2_6/prodata/1/ina/6A_COMB.seq:*
4: /cgn2_6/prodata/1/ina/6B_COMB.seq:*
5: /cgn2_6/prodata/1/ina/6C_COMB.seq:*
6: /cgn2_6/prodata/1/ina/backfiles1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	12.2	42.1	27	6	5258283-10 Patent No. 5258283
2	12.2	42.1	69	2	US-08-410-654B-30 Sequence 30, Appl
3	12.2	42.1	69	2	US-08-474-851-30 Sequence 30, Appl
4	12.2	42.1	69	2	US-08-481-560-30 Sequence 30, Appl
5	11.8	40.7	21	2	US-08-747-536-10 Sequence 10, Appl
6	11.6	40.0	36	4	US-08-218-369-7 Sequence 7, Appl
7	11.6	40.0	36	4	US-08-218-369-15 Sequence 15, Appl
8	11.6	40.0	36	5	PCT-US95-03742-7 Sequence 7, Appl
9	11.6	40.0	36	5	PCT-US95-03742-15 Sequence 15, Appl
10	11.2	38.6	25	1	US-08-741-881-28 Sequence 28, Appl
11	11.2	38.6	25	1	US-08-739-158-28 Sequence 28, Appl
12	11.2	38.6	25	3	US-08-739-167-28 Sequence 28, Appl
13	11.2	38.6	25	3	US-08-404-796-28 Sequence 28, Appl
14	11.2	38.6	25	3	US-08-931-869-28 Sequence 28, Appl
15	11.2	38.6	25	3	US-09-350-399-28 Sequence 28, Appl
16	11.2	38.6	33	1	US-08-741-881-29 Sequence 29, Appl
17	11.2	38.6	33	1	US-08-739-158-29 Sequence 29, Appl
18	11.2	38.6	33	3	US-08-739-167-29 Sequence 29, Appl
19	11.2	38.6	33	3	US-08-404-796-29 Sequence 29, Appl
20	11.2	38.6	33	3	US-08-931-869-29 Sequence 29, Appl
21	11.2	38.6	33	4	US-09-350-399-29 Sequence 29, Appl
22	11.2	38.6	36	2	US-08-642-045B-17 Sequence 17, Appl
23	11.2	38.6	36	4	US-08-852-268-17 Sequence 17, Appl
24	11.2	38.6	70	4	US-09-364-380-29 Sequence 29, Appl
25	11.2	37.9	31	1	US-08-323-531-71 Sequence 71, Appl
26	11.2	37.9	31	1	US-08-198-094-71 Sequence 71, Appl
27	11.2	37.9	31	3	US-08-480-640A-119 Sequence 119, App

c	28	11	37.9	31	3	US-08-295-802-119	Sequence 119, App
c	29	11	37.9	31	4	US-08-107-794A-71	Sequence 71, Appl
c	30	11	37.9	31	4	US-08-488-237A-119	Sequence 119, App
c	31	11	37.9	31	4	US-08-375-992A-119	Sequence 119, App
c	32	11	37.9	31	5	PCT-US93-07424-71	Sequence 71, Appl
c	33	11	37.9	31	5	PCT-US95-02087-71	Sequence 71, Appl
c	34	11	37.9	70	2	US-08-488-402A-127	Sequence 127, App
c	35	11	37.9	70	2	US-08-484-552A-127	Sequence 127, App
c	36	11	37.9	70	5	PCT-US96-09472-127	Sequence 127, App
c	37	10.8	37.2	19	1	US-08-365-109B-1	Sequence 1, Appl
c	38	10.8	37.2	19	1	US-08-365-109B-3	Sequence 3, Appl
c	39	10.8	37.2	20	4	US-09-560-594-53	Sequence 53, App
c	40	10.8	37.2	25	4	US-08-943-731-336	Sequence 336, App
c	41	10.8	37.2	27	4	US-09-253-396A-137	Sequence 137, App
c	42	10.8	37.2	45	1	US-08-171-389-130	Sequence 130, App
c	43	10.8	37.2	45	1	US-08-171-389-342	Sequence 342, App
c	44	10.8	37.2	45	1	US-08-123-936-130	Sequence 130, App
c	45	10.8	37.2	45	1	US-08-123-936-342	Sequence 342, App

ALIGNMENTS

RESULT 1
5258283-10
Patent No. 5258283
APPLICANT: FRAZIER, MARTIN E.; MALAVIA, LOUIS P.; SAMUEL, JAMES E.; BACA, OSWALD G.
TITLE OF INVENTION: DETECTION AND DIFFERENTIATION OF COXIELLA BURNETII IN BIOLOGICAL FLUIDS
NUMBER OF SEQUENCES: 17
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/425, 856
FILING DATE: 23-Oct-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 927,779
FILING DATE: 05-NOV-1986
APPLICATION NUMBER: 795,207
FILING DATE: 05-NOV-1985
SEQ ID NO:10:
LENGTH: 27
5258283-10

Query Match 42.1%; Score 12.2; DB 6; Length 27;
Best Local Similarity 40.9%; Pred. No. 1.4e+02;
Matches 9; Conservative 5; Mismatches 8; Indels 0; Gaps 0;
QY 4 gauncuunuuuaagccnang 25
DB 4 ggtcttgataagccaatg 25

RESULT 2
US-08-410-654B-30
Sequence 30, Application US/08410654B
Patent No. 5833976
GENERAL INFORMATION:
APPLICANT: Rene de Waal Malefyt
APPLICANT: Di-Hwei Hsu
APPLICANT: Anne O'Garra
APPLICANT: Hergen Splits
TITLE OF INVENTION: Use of Interleukin-10 to Treat
NUMBER OF SEQUENCES: 61
CORRESPONDENCE ADDRESS:
ADDRESSER: Schering-Plough Corporation
CITY: Kenilworth
STATE: New Jersey
COUNTRY: USA
ZIP: 07033
COMPUTER READABLE FORM:

```

CEDIUM TYPE: Floppy disk
COMPUTER: Macintosh
OPERATING SYSTEM: 7.5.3
SOFTWARE: Microsoft Word 5.1a
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/410,654B
FILING DATE: 24-MAR-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/229,854
FILING DATE: 19-APR-1994
APPLICATION NUMBER: US 07/926,853
FILING DATE: 06-AUG-1992
APPLICATION NUMBER: US 07/742,129
FILING DATE: 06-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: Foule, Cynthia L.
REGISTRATION NUMBER: 32,364
REFERENCE/DOCKET NUMBER: DX0221K01
TELECOMMUNICATION INFORMATION:
TELEPHONE: 908-298-7987
TELEFAX: 908-298-5388
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 69 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (oligonucleotide)
OS-08-410-654B-30

```

Query Match	42.18;	Score 12.2;	DB 2;	Length 69;
Best Local Similarity	43.5%;	Pred. No. 1.7e+02;		
Matches 10; Conservative	4;	Mismatches 9;	Indels 0;	Gaps 0;

Qy 5 auncuunguaagcccnangng 27
| : | : : | | | | |
Db 11 ATGCCTTAATAAGCTCCAAGAG 33

RESULT 3
US-08-474-851-30
; Sequence 30, Application US/08474851
; Patient No. 5837232
; GENERAL INFORMATION:
APPLICANT: Rene de Waal Malefyt
APPLICANT: Di-Hwei Hsu
APPLICANT: Anne O'Garra
APPLICANT: Hergen Spits
TITLE OF INVENTION: Use of An Interleukin-10 Antagonist to Treat
TITLE OF INVENTION: A B Cell Mediated Autoimmune Disorder
NUMBER OF SEQUENCES: 61
CORRESPONDENCE ADDRESS:
ADDRESSEE: Schering-Plough Corporation
STREET: 2000 Gallopington Hill Road
CITY: Kenilworth
STATE: New Jersey
COUNTRY: USA
ZIP: 07033
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: Macintosh
OPERATING SYSTEM: 7.5.3
SOFTWARE: Microsoft Word 6.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08-474, 851
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/410, 654
FILING DATE: 24-MAR-1995
APPLICATION NUMBER: US 08/229, 854

```

1      FILING DATE: 19-APR-1994
2      APPLICATION NUMBER: US 07/926, 853
3      FILING DATE: 06-AUG-1992
4      APPLICATION NUMBER: US 07//42, 129
5      FILING DATE: 06-AUG-1991
6      ATTORNEY/AGENT INFORMATION:
7      NAME: Foulke, Cynthia L.
8      REGISTRATION NUMBER: 32,364
9      REFERENCE/DOCKET NUMBER: DX0221K01GD
10     TELECOMMUNICATION INFORMATION:
11     TELEPHONE: 908-298-2987
12     TELEFAX: 908-298-5388
13     INFORMATION FOR SEQ ID NO: 30:
14     SEQUENCE CHARACTERISTICS:
15     LENGTH: 69 base pairs
16     TYPE: nucleic acid
17     STRANDEDNESS: double
18     TOPOLOGY: linear
19     MOLECULE TYPE: DNA (oligonucleotide)
20     US-08-474-851-30

```

Query Match	42.1%;	Score 12.2;	DB 2;	Length 69;
Best Local Similarity	43.5%;	Pred. No. 1.7e+02;		
Matches 10; Conservative	4;	Mismatches 9;	Indels 0;	Gaps 0;

Qy 5 auncuunguaagcccnangng 27
| : | : : | | | | |
Db 11 ATGCCTTAATAAGCTCCAAGAG 33

RESULT 4
US-08-481-560-30
Sequence 30, Application US/08481560
Patent No. 5837293
GENERAL INFORMATION:
APPLICANT: Rene de Waal Malefyt
APPLICANT: Di Hwei Hsu
APPLICANT: Anne O'Garra
APPLICANT: Hergen Spits
TITLE OF INVENTION: Use of Interleukin-10 to Modulate
TITLE OF INVENTION: Inflammation or T-cell Mediated
TITLE OF INVENTION: Immune Function
NUMBER OF SEQUENCES: 61
CORRESPONDENCE ADDRESS:
ADDRESSEE: Schering-Plough Corporation
STREET: 2000 Gallopang Hill Road
CITY: Kenilworth
STATE: New Jersey
COUNTRY: USA
ZIP: 07033
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: Macintosh
OPERATING SYSTEM: 7.5.3
SOFTWARE: Microsoft Word 6.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/481,560
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/410,654
FILING DATE: 24-MAR-1995
APPLICATION NUMBER: US 08/229,854
FILING DATE: 19-APR-1994
APPLICATION NUMBER: US 07/926,853
FILING DATE: 06-AUG-1992
APPLICATION NUMBER: US 07/742,129
FILING DATE: 06-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: Foulke, Cynthia L.
REGISTRATION NUMBER: 32,364
REFERENCE/DOCKET NUMBER: DX0221KO1GC


```
STREET: 1100 Peachtree Street, Suite 2800
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30309-4530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/218,369
FILING DATE: 28-MAR-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Pabst, Patrea L.
REGISTRATION/DOCKET NUMBER: 31,284
TELECOMMUNICATION INFORMATION:
TELEPHONE: (404) 815-6508
TELEFAX: (404) 815-6555
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 36 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
FEATURE:
NAME/KEY: misc_feature
LOCATION: 1..36
OTHER INFORMATION: /note= "Nucleotides 5 through 36 are complementary to nucl
US-08-218-369-15

Query Match          40.0%; Score 11.6; DB 4; Length 36;
Best Local Similarity 41.7%; Pred. No. 3.4e+02;
Matches 10; Conservative 4; Mismatches 10; Indels 0; Gaps 0;

QY 4 gauncuununguaagcccnangng 27
   |||:::|:| ||| |
Db 10 GAAGCTTAGTGAGGCCCATGAG 33

RESULT 8
-US95-03742-7/C
Sequence 7, Application PC/TUS9503742
GENERAL INFORMATION:
APPLICANT: The UAB Research Foundation
TITLE OF INVENTION: Ligands Added to Adenovirus Fiber
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSER: Patrea L. Pabst
STREET: 2800 One Atlantic Center
STREET: 1201 West Peachtree Street
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30309-3450
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/03742
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Pabst, Patrea L.
REGISTRATION/DOCKET NUMBER: 31,284
TELECOMMUNICATION INFORMATION:
TELEPHONE: (404) 815-6508
TELEFAX: (404) 815-6555
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 36 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
FEATURE:
NAME/KEY: misc_feature
LOCATION: 1..36
```

```
REFERENCE/DOCKET NUMBER: IG1101
TELECOMMUNICATION INFORMATION:
TELEPHONE: (404) 873-8794
TELEFAX: (404) 873-8795
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 36 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
FEATURE:
NAME/KEY: misc_feature
LOCATION: 1..36
OTHER INFORMATION: /note= "Nucleotide sequence
PCT-US95-03742-7

Query Match          40.0%; Score 11.6; DB 5; Length 36;
Best Local Similarity 41.7%; Pred. No. 3.4e+02;
Matches 10; Conservative 4; Mismatches 10; Indels 0; Gaps 0;

QY 4 gauncuununguaagcccnangng 27
   |||:::|:| ||| |
Db 31 GAAGCTTAGTGAGGCCCATGAG 8

RESULT 9
PCT-US95-03742-15
Sequence 15, Application PC/TUS9503742
GENERAL INFORMATION:
APPLICANT: The UAB Research Foundation
TITLE OF INVENTION: Ligands Added to Adenovirus Fiber
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSER: Patrea L. Pabst
STREET: 2800 One Atlantic Center
STREET: 1201 West Peachtree Street
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30309-3450
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/03742
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Pabst, Patrea L.
REGISTRATION/DOCKET NUMBER: 31,284
TELECOMMUNICATION INFORMATION:
TELEPHONE: (404) 873-8794
TELEFAX: (404) 873-8795
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 36 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
FEATURE:
NAME/KEY: misc_feature
LOCATION: 1..36
```



```

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/739,167
FILING DATE: 30-OCT-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: McMasters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 930049.423C7 / 1146.008B
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:
LENGTH: 25 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

```

Query Match	38.68;	Score 11.2;	DB 2;	Length 25;
Best Local Similarity	36.48;	Pred. No. 5.4e+02;		
Matches	8;	Conservative	5;	Mismatches 9;
				Indels

Qy 6 uncuuunguaagcccnangng 27
: | :: | : | | | |
Db 24 TCCTTTAGGTTAGCCGTTACAAG 3

RESULT 13
US-08-404-796-28/C
; Sequence 28, Application US/08404796

```

1  GENERAL INFORMATION:
2  APPLICANT:  Dubensky Jr, Thomas W
3  APPLICANT:  Polo, John M.
4  APPLICANT:  Idanez, Carlos E.
5  APPLICANT:  Chang, Stephen M.W.
6  APPLICANT:  Jolly, Douglas J.
7  APPLICANT:  Driver, David A.
8  APPLICANT:  Bell, Barbara A.
9  TITLE OF INVENTION:  EUKARYOTIC LAYERED VECTOR INITIATION SYSTEMS
10 NUMBER OF SEQUENCES:  18

```

```

;      TOPOLOGY: linear
US-08-404-796-28

```

Query Match	38.6%	Pred 11.2%	DB 3%	Length 25%
Best Local Similarity	36.4%	Pred No. 5.4e+02		
Matches	8	Mismatches	9	Indels 0
				Gaps 0

QY 6 uncuuunguaagcccnangng 27
: |: : |: |: |
Db 24 TCCTTTAGGTTAGCCGTACAAG 3

RESULT 14
US-08-931-869-28/c
; Sequence 28, Application US/08931869
; Patent No. 6015694

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

Query Match	38.6%	Score	11.2	DB	3	Length	25
Best Local	Similarity	36.4%	Pred. No.	5.4e+02			
Matches	8	Conservative	5	Mismatches	9	Indels	0
						Gaps	0

Qy 6 uncuuunguaagcccnangng 27
: |:: |:: ||| |
Db 24 TCCTTTAGGTTAGCCGTACAAG 3

RESULT 15
US-09-350-399-28/c

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 29, 2002, 18:34:27 ; Search time 1874.63 Seconds
(without alignments)
208.794 Million cell updates/sec

Title: US-09-310-844C-23
Perfect score: 29
Sequence: 1 nngauuncuunguagccnangnngn 29

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 1.0

Searched: 13736207 seqs, 674847542 residues

Total number of hits satisfying chosen parameters: 297742

Minimum DB seq length: 0
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
EST:*
1: em_estba:*
2: em_esthum:*
3: em_estmu:*
4: em_estnu:*
5: em_estov:*
6: em_estipl:*
7: em_estiro:*
8: em_hic:*
9: gb_est1:*
10: gb_est2:*
11: gb_hic:*
12: gb_gss:*
13: em_gss_hum:*
14: em_gss_inv:*
15: em_gss_pln:*
16: em_gss_vrt:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	13	44.8	46	12	AZ833686 2M0115L20
2	12.8	44.1	76	12	AQ025263 EP(3)3081
3	12.8	44.1	86	12	CNS0210D
4	12.4	42.8	52	9	AA700959
5	12.4	42.8	70	9	AA468615
6	12.2	42.1	48	12	A2503560
7	12.2	42.1	75	12	A2453746
8	12.2	42.1	86	10	A2453746
9	12.2	42.1	92	10	BI305219
10	12.2	42.1	96	10	H81976
11	12.2	42.1	98	12	A2767813
12	11.8	40.7	40	9	AA975071
13	11.8	40.7	49	10	BE970036
14	11.8	40.7	65	9	AA733449
15	11.8	40.7	70	9	A1767928
16	11.8	40.7	70	12	BH216023
17	11.8	40.7	75	12	CNS01561

C 18	11.8	40.7	83	10	BE845147	BE845147 AD07E12T7
C 19	11.8	40.7	87	10	BE845145	BE845145 AD07E06T7
C 20	11.8	40.7	86	12	AA807716	AA807716 2M0070D13
C 21	11.8	40.7	93	9	AA488835	AA488835 aa54h10.r
C 22	11.8	40.7	95	12	A2598556	A2598556 1M0413K23
C 23	11.8	40.7	98	9	AW311302	AW311302 sg35b11.y
C 24	11.6	40.0	49	10	U44334	U44334 ENU44334 As
C 25	11.6	40.0	58	9	A1584456	A1584456 fb93h12.x
C 26	11.6	40.0	70	9	A1E14489	A1E14489 wj73g11.x
C 27	11.6	40.0	79	12	A236769	A236769 1M0067L12
C 28	11.6	40.0	81	12	BH627770	BH627770 1007076E0
C 29	11.6	40.0	85	9	AA617776	AA617776 np99e08.s
C 30	11.6	40.0	85	10	W20254	W20254 zb42a10.r1
C 31	11.6	40.0	93	12	AZ832088	AZ832088 2M0112D15
C 32	11.6	40.0	94	9	AA558052	AA558052 n118f06.s
C 33	11.6	40.0	97	9	A1181481	A1181481 uc62g11.r
C 34	11.6	40.0	100	9	A1148625	A1148625 qc62g05.x
C 35	11.6	40.0	100	10	H13996	H13996 EST00022 Ch
C 36	11.4	39.3	32	12	HSMA42B09	HSMA42B09 H.sapiens D
C 37	11.4	39.3	40	12	TA253H010	TA253H010 T. brucei
C 38	11.4	39.3	46	9	A1867082	A1867082 w196e09.x
C 39	11.4	39.3	66	9	AA247859	AA247859 j3371.seq
C 40	11.4	39.3	67	12	TA113E04Q	TA113E04Q T. brucei
C 41	11.4	39.3	73	9	A1900474	A1900474 sc11b10.y
C 42	11.4	39.3	75	12	BH609927	BH609927 HIV22C11
C 43	11.4	39.3	76	9	AA988261	AA988261 os16a07.s
C 44	11.4	39.3	81	9	AA738756	AA738756 vv67B08.r
C 45	11.4	39.3	85	12	AZ830379	AZ830379 2M0109A09

ALIGNMENTS

RESULT 1
AZ833686 46 bp DNA linear GSS 20-FEB-2001
LOCUS 2M0115L20R Mouse 10kb plasmid UGCC1M library Mus musculus genomic
DEFINITION clone UGCC2M0115L20 R, DNA sequence.

ACCESSION AZ833686
VERSION AZ833686.1 GI:13003594

KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0115 row, L column: 20
Seq primer: CACACGAGAAACGCTATGACC
Class: plasmid ends
High quality sequence stop: 46.
Location/Qualifiers
1..46
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UCC2M0115L20"
/clone_lib="Mouse 10kb plasmid UGCC1M library"

REFERENCE
1 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
1 (bases 1 to 86)

DEFINITION 601680150F1 NIH_MGC_78 Homo sapiens cDNA clone IMAGE:3950172 5', mRNA sequence.

ACCESSION BE970036

VERSION BE970036.1 GI:10582969

KEYWORDS EST.

SOURCE human.

ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 49)

AUTHORS NIH-MGC <http://mhc.nci.nih.gov/>.

TITLE National Institutes of Health, Mammalian Gene Collection (MGC)

JOURNAL Unpublished (1999)

COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: CLONTECH Laboratories, Inc.
cDNA Library Preparation: CLONTECH Laboratories, Inc.
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>
Place: LBL816 row: d column: 13
High quality sequence stop: 49.

FEATURES
source
1. 49
Location/Qualifiers
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:3950172"
/clone_1lb="NIH_MGC_78"
/lab_host="DH10B (T1 Phage-resistant)"
/note="Organ: pancreas; Vector: pDNR-LIB (Clontech); Site_1: SfiI (ggcgccgcgcgc); Site_2: SfiI (ggcattatggcc); 5' and 3' adaptors were used in cloning as follows: 5' adaptor sequence: 5'-ATCTGAGAGCGCGCGCGCATG-dT(30)BN-3' (where B = A, C, or G and N = A, C, G, or T). Average insert size 1.2 kb (range 0.5-4.0 kb). 14/15 colonies contained inserts by PCR. This library was enriched for full-length clones and was constructed by Clontech Laboratories (Palo Alto, CA)."

BASE COUNT 20 a 7 c 12 g 10 t

ORIGIN

Query Match 40.7%; Score 11.8; DB 10; Length 49;
Best Local Similarity 45.0%; Pred. No. 5.9e+04;
Matches 9; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

6 uncuununguagccnang 25
1 : : : : | | | | | | |
48 TTTTTCATGCAAGCCCCAGG 29

RESULT 14
AA733449 65 bp mRNA linear EST 07-JAN-1998
LOCUS vt73h08.r1 Barstead mouse irradiated colon MFLRB7 Mus musculus cDNA
DEFINITION Clone IMAGE:1176831 5' similar to gb:X06617 40S RIBOSOMAL PROTEIN S11 (HUMAN);, mRNA sequence.

ACCESSION AA733449

VERSION AA733449.1 GI:2755116

KEYWORDS EST.

SOURCE house mouse.

ORGANISM Mus musculus

REFERENCE 1 (bases 1 to 65)

AUTHORS Marra, M., Hillier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T., Geisel, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M., Schellenberg, K., Steptoe, M., Tan, F., Underwood, K., Moore, B., Theising, B., Wylie, T., Lennon, G., Soares, B., Wilson, R. and Waterston, R.

TITLE The WashU-HIMI Mouse Est Project

JOURNAL Unpublished (1996)

COMMENT Contact: Marra M/Mouse EST Project
WashU-HIMI Mouse EST Project
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@watson.wustl.edu
This clone is available royalty-free through LLNL; contact the IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:634679
Trace considered overall poor quality
Seq primer: -28m13 rev2 ET from Amersham
High quality sequence stop: 1.

FEATURES
source
1. 65
Location/Qualifiers
/organism="Mus musculus"
/strain="FVB/N"
/db_xref="taxon:10090"
/clone="IMAGE:1176831"
/clone_1lb="Barstead mouse irradiated colon MFLRB7"
/dev_stage="8 weeks"
/lab_host="DH10B"
/note="Vector: pT7/3D-Pac (Pharmacia) with a modified polylinker. Site_1: EcoRI; Site_2: NotI; Tissue obtained from 8 week old mouse. Colon was harvested 72 hours after irradiation with 1400 Gys. 1st strand cDNA was primed with a Not I - oligo(dT) primer
15'GTGTGCAATCTGAGTGGAGCGCGCGCCCGCTTTTTTTTTTTTTTTTTTTT
T 3'; double-stranded cDNA was ligated to Eco RI adaptors (AATTCGATCCTTG), digested with Not I and cloned into the Not I and Eco RI sites of the modified pT773 vector. Library constructed by Bob Barstead."

BASE COUNT 23 a 15 c 16 g 11 t

ORIGIN

Query Match 40.7%; Score 11.8; DB 9; Length 65;
Best Local Similarity 44.4%; Pred. No. 6e+04;
Matches 8; Conservative 5; Mismatches 5; Indels 0; Gaps 0;

4 gauncuununguagccc 21
1 : : : : | | | | | | |
44 GCTGCTTTTGCTAGCAC 27

RESULT 15
A1767928 70 bp mRNA linear EST 21-DEC-1999
LOCUS w199c01.x1 NCI-CGAP_K1d12 Homo sapiens cDNA clone IMAGE:2401440 3'
DEFINITION Similar to SW:RT14_HUMAN P78537 RT14 PROTEIN; mRNA sequence.

ACCESSION A1767928

VERSION A1767928.1 GI:5234426

KEYWORDS EST.

SOURCE human.

ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 70)

AUTHORS NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.

TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index

JOURNAL Unpublished (1997)

COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R. Emmert-Buck, M.D., Ph.D.
cDNA Library Preparation: M. Bento Soares, Ph.D.
DNA Sequencing by: Greg Lennon, Ph.D.
Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:

www.bio.lnl.gov/bdrp/image/image.html

Trace considered overall poor quality
Insert Length: 574 Std Error: 0.00
Seq primer: -40UP from Gibco
High quality sequence stop: 1.
Location/Qualifiers

FEATURES

Source

1. 70
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2401440"
/clone_1b="NCI_CGAP_Kid12"
/tissue_type="2_pooled tumors (clear cell type)"
/lab_host="DH10B"
/note="Organ: kidney; Vector: p1773D-Pac (Pharmacia) with a modified polylinker; Site.1: Not I; Site.2: Eco RI; Plasmid DNA from the normalized library NCI_CGAP_Kids was prepared, and ss circles were made in vitro. Following HAP purification, this DNA was used as tracer in a subtractive hybridization reaction. The driver was PCR-amplified cDNAs from a pool of 5,000 clones made from the same library (clonoids 1323912-1325831, 1471368-1472903 and 1492104-1493255). Subtraction by Bento Soares and M. Fatima Bonafide."

BASE COUNT 20 a 24 c 6 g 20 t
ORIGIN

Query Match

40.7%: Score 11.8; DB 9; Length 70;

Best Local Similarity 47.4%: Pred. No. 6e+04; 6; Indels 0; Gaps 0;

Matches 9; Conservative 4; Mismatches 0;

5 auncununguaagccca 23

1: |::: | | | | |

b 46 ATTCTTACGAAGCCAGA 64

Search completed: April 29, 2002, 22:38:40
Job time: 14653 sec